Shamburg News · 8-K filed Oct 8, 2026, 6:52 AM EDT
Atrium Therapeutics Announces $50 Million Private Placement of Common Stock and Pre-Funded Warrants
RNA · Atrium Therapeutics, Inc.
- Financing
- Material agreement
- Other event
- Materiality: high
Atrium Therapeutics, Inc. entered into a securities purchase agreement on October 7, 2026 to sell 5,170,384 shares of common stock at $7.93 per share and pre-funded warrants for up to 1,134,930 shares, for aggregate gross proceeds of approximately $50 million before placement agent fees and offering expenses. The offering is expected to close on or about October 9, 2026, and the company agreed to file a resale registration statement within 50 days of closing. The company estimates the net proceeds together with existing cash will fund operations through 2028.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 8.01, 9.01, accession 0001193125-26-417402.
Written from the filing by Shamburg Markets. Figures are as reported by the company.